Get the Stockscreener App
10.64
0.65%
-0.07
Urogen Pharma Ltd Stock (URGN) Forecast
The Urogen Pharma Ltd (URGN) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $10.71, representing a +0.65% increase from the current price of $10.64. The highest analyst price target is $12.51, and the lowest is $8.9073.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month URGN Price Target
Average 6.3014
(-40.78% Downside)
Is Urogen Pharma Ltd (URGN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 29.98 | Buy |
| STOCH(9,6) | 10.89 | Buy |
| STOCHRSI(14) | 2.9037 | Buy |
| MACD(12,26) | -0.3646 | Sell |
| ADX(14) | 19.20 | Neutral |
| William %R | -94.58 | Buy |
| CCI(14) | -99.22 | Neutral |
Buy: 4
Sell: 1
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
11.32
Sell
|
11.24
Sell
|
| MA20 |
11.88
Sell
|
11.58
Sell
|
| MA50 |
12.05
Sell
|
12.09
Sell
|
| MA100 |
12.91
Sell
|
12.78
Sell
|
| MA200 |
13.92
Sell
|
13.61
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, URGN could be considered a Strong Sell, with 17 technical analysis indicators signaling 4 Buy signals, 11 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on URGN, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 29.98 indicates that URGN is oversold. This indicates that URGN price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 10.89 indicates that URGN is oversold. This indicates that URGN price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 2.9037 indicates that URGN is oversold. This suggests that URGN price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 19.2 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -99.22 indicates that URGN is still oversold but not to an extreme extent.
Long-term URGN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Urogen Pharma Ltd financial reports and earnings history, Urogen Pharma Ltd (URGN) stock could reach $12.19 by 2030, $27.57 by 2040 and $73.78 by 2050. See the projected annual prices until 2050 of the Urogen Pharma Ltd stock below:
- Urogen Pharma Ltd (URGN) is expected to reach an average price of $8.1718 in 2035, with a high prediction of $10.16 and a low estimate of $8.9268. This indicates an $-23.20% rise from the last recorded price of $10.64.
- Urogen Pharma Ltd (URGN) stock is projected to chart a bullish course in 2040, with an average price target of $25.48, representing an $139.44% surge from its current level. The forecast ranges from a conservative $27.38 to a sky-high $27.57.
- Our analysts predict Urogen Pharma Ltd (URGN) to jump 339.17% by 2045, soaring from $48.34 to an average price of $46.73, potentially reaching $47.84. While $48.34 is the low estimate, the potential upside is significant.
- Urogen Pharma Ltd (URGN) stock is expected to climb by 2050, reaching an average of $70.18, a $559.62% jump from its current level. However, a wide range of estimates exists, with high and low targets of $73.78 and $71.17, respectively, highlighting the market's uncertainty.
Urogen Pharma Ltd Stock (URGN) Year by Year Forecast
Urogen Pharma Ltd Stock (URGN) Price Forecast for 2025
Urogen Pharma Ltd Stock (URGN) is expected to reach an average price of $6.3014 in 2025, with a high prediction of $12.56 and a low estimate of $0.0388. This indicates an -40.78% fall from the last recorded price of $10.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $9.4056 | $8.9073 | $12.51 | -11.60% |
| February, 2025 | $7.2467 | $5.5567 | $12.56 | -31.89% |
| March, 2025 | $4.4878 | $3.7078 | $8.315 | -57.82% |
| April, 2025 | $4.7483 | $4.3906 | $8.2106 | -55.37% |
| May, 2025 | $1.8428 | $1.2833 | $4.1899 | -82.68% |
| June, 2025 | $3.1639 | $0.0388 | $4.9856 | -70.26% |
| July, 2025 | $7.3928 | $1.5523 | $8.7828 | -30.52% |
| August, 2025 | $2.3389 | $2.0889 | $9.7206 | -78.02% |
| September, 2025 | $2.3601 | $0.7151 | $5.0545 | -77.82% |
| October, 2025 | $0.164 | $0.7614 | $5.8778 | -98.46% |
| November, 2025 | $1.0349 | $0.2841 | $2.3695 | -90.27% |
| December, 2025 | $2.459 | $0.2938 | $3.2734 | -76.89% |
Urogen Pharma Ltd Stock (URGN) Price Forecast for 2026
The predicted value for Urogen Pharma Ltd (URGN) in 2026 is set at an average of $4.5029. Estimates vary from a peak of $8.9834 to a trough of $0.0223, indicating an -57.68% surge from the present price of $10.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.6501 | $0.0601 | $5.9845 | -93.89% |
| February, 2026 | $0.8188 | $0.0971 | $1.3056 | -92.30% |
| March, 2026 | $0.6023 | $0.4023 | $2.2223 | -94.34% |
| April, 2026 | $5.9762 | $0.5801 | $8.9834 | -43.83% |
| May, 2026 | $1.0173 | $0.111 | $5.899 | -90.44% |
| June, 2026 | $0.4584 | $0.2284 | $1.9601 | -95.69% |
| July, 2026 | $3.2777 | $0.7168 | $2.7068 | -69.19% |
| August, 2026 | $0.9566 | $0.6793 | $0.8661 | -91.01% |
| September, 2026 | $3.0527 | $1.971 | $2.5627 | -71.31% |
| October, 2026 | $2.3216 | $2.6216 | $1.9499 | -78.18% |
| November, 2026 | $0.0396 | $0.5704 | $2.456 | -99.63% |
| December, 2026 | $0.5365 | $0.0223 | $1.1023 | -94.96% |
Urogen Pharma Ltd Stock (URGN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Urogen Pharma Ltd (URGN) is $4.9335, with a high forecast of $9.7871 and a low forecast of $0.0799. This indicates an -53.63% decrease from the last price of $10.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.0354 | $0.8338 | $0.5718 | -99.67% |
| February, 2027 | $4.8343 | $0.0799 | $2.7129 | -54.56% |
| March, 2027 | $6.9204 | $5.0315 | $5.2154 | -34.96% |
| April, 2027 | $7.9293 | $7.7749 | $7.2843 | -25.48% |
| May, 2027 | $8.8782 | $8.9065 | $8.2382 | -16.56% |
| June, 2027 | $9.9043 | $9.1554 | $9.7871 | -6.91% |
| July, 2027 | $7.0232 | $7.526 | $6.8015 | -33.99% |
| August, 2027 | $8.0521 | $7.1902 | $7.6721 | -24.32% |
| September, 2027 | $9.8282 | $8.5893 | $9.4382 | -7.63% |
| October, 2027 | $8.4471 | $8.9971 | $9.4254 | -20.61% |
| November, 2027 | $6.0959 | $6.7259 | $6.3317 | -42.71% |
| December, 2027 | $6.0421 | $6.3954 | $6.1876 | -43.21% |
Urogen Pharma Ltd Stock (URGN) Price Forecast for 2028
In 2028, Urogen Pharma Ltd (URGN) is projected to reach an average price of $3.532, with a high projection of $6.6509 and a low estimate of $0.4131. This indicates an -66.80% fall from the last price of $10.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $6.7809 | $6.4493 | $6.6509 | -36.27% |
| February, 2028 | $5.8298 | $6.3476 | $6.3632 | -45.21% |
| March, 2028 | $2.0359 | $2.1959 | $4.197 | -80.87% |
| April, 2028 | $6.0848 | $2.6232 | $5.1798 | -42.81% |
| May, 2028 | $5.2709 | $5.3693 | $5.1809 | -50.46% |
| June, 2028 | $4.7998 | $5.1698 | $4.4581 | -54.89% |
| July, 2028 | $3.8087 | $3.6743 | $3.477 | -64.20% |
| August, 2028 | $3.4048 | $2.7276 | $2.5459 | -68.00% |
| September, 2028 | $3.7137 | $3.9137 | $3.3992 | -65.10% |
| October, 2028 | $0.4526 | $1.0426 | $3.8074 | -95.75% |
| November, 2028 | $2.2987 | $0.887 | $2.0487 | -78.40% |
| December, 2028 | $1.4776 | $0.4131 | $1.2369 | -86.11% |
Urogen Pharma Ltd Stock (URGN) Price Forecast for 2029
The 2029 price forecast for Urogen Pharma Ltd Stock (URGN) is $6.4199 on average, with a high prediction of $12.72 and a low estimate of $0.1152. This represents an -39.66% decrease from the previous price of $10.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $10.10 | $1.7748 | $12.31 | -5.11% |
| February, 2029 | $7.3674 | $6.3391 | $12.72 | -30.76% |
| March, 2029 | $4.7686 | $4.2336 | $7.8802 | -55.18% |
| April, 2029 | $2.1697 | $1.8097 | $5.4941 | -79.61% |
| May, 2029 | $0.7936 | $0.1152 | $3.0224 | -92.54% |
| June, 2029 | $2.5747 | $0.3064 | $3.2719 | -75.80% |
| July, 2029 | $4.7558 | $2.5275 | $5.9702 | -55.30% |
| August, 2029 | $5.7197 | $3.2086 | $6.4197 | -46.24% |
| September, 2029 | $7.3208 | $5.4725 | $10.05 | -31.20% |
| October, 2029 | $6.2547 | $4.3019 | $9.0191 | -41.22% |
| November, 2029 | $4.4358 | $3.023 | $8.7775 | -58.31% |
| December, 2029 | $10.20 | $4.3386 | $9.23 | -4.14% |
Urogen Pharma Ltd Stock (URGN) Price Forecast for 2030
Urogen Pharma Ltd Stock (URGN) is expected to reach an average price of $18.70 in 2030, with a high forecast of $25.15 and a low forecast of $12.25. This signifies an +75.76% surge from the last price of $10.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $13.38 | $12.25 | $12.19 | +25.77% |
| February, 2030 | $15.25 | $14.35 | $13.41 | +43.33% |
| March, 2030 | $13.65 | $14.07 | $15.03 | +28.27% |
| April, 2030 | $13.99 | $16.24 | $13.98 | +31.44% |
| May, 2030 | $22.93 | $12.79 | $22.40 | +115.49% |
| June, 2030 | $24.53 | $24.36 | $23.83 | +130.50% |
| July, 2030 | $16.57 | $19.86 | $23.51 | +55.71% |
| August, 2030 | $10.66 | $13.61 | $14.06 | +0.15% |
| September, 2030 | $13.33 | $12.29 | $12.43 | +25.31% |
| October, 2030 | $16.54 | $14.89 | $14.16 | +55.46% |
| November, 2030 | $26.14 | $16.94 | $16.22 | +145.71% |
| December, 2030 | $25.35 | $26.95 | $25.15 | +138.26% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):